AstraZeneca’s EMERALD‑3 Phase III study demonstrated a statistically significant and clinically meaningful improvement in progression‑free survival for patients with embolization‑eligible, unresectable hepatocellular carcinoma. The combination of Imfinzi (durvalumab) and Imjudo (tremelimumab) with lenvatinib and transarterial chemoembolization (TACE) outperformed standard care, which consists of TACE alone, and a trend toward improved overall survival was observed in the interim analysis.
The trial enrolled patients who could not undergo surgical resection but were eligible for locoregional embolization. By adding the dual immunotherapy STRIDE regimen to lenvatinib and TACE, the study sought to address the unmet need for systemic treatment options that can delay disease progression in this high‑risk population. The design mirrors the earlier HIMALAYA Phase III trial, which established durable overall survival benefits for the STRIDE regimen in advanced, unresectable disease.
Susan Galbraith, Executive Vice President of Oncology Haematology R&D, said, "EMERALD‑3 now shows that bringing the dual immunotherapy STRIDE regimen earlier, alongside TACE and lenvatinib, can further improve outcomes in earlier‑stage liver cancer. This builds on the HIMALAYA Phase III trial data in patients with advanced, unresectable disease, where the STRIDE regimen has already demonstrated durable overall survival benefit. We are discussing these positive data with global regulatory authorities while awaiting the final results from the key secondary endpoints."
Ghassan Abou‑Alfa, principal investigator of EMERALD‑3, added, "Dual immunotherapy with durvalumab and tremelimumab in the STRIDE regimen represents a meaningful advance for patients with embolisation‑eligible liver cancer, who currently lack systemic treatment options to keep their cancer from progressing or recurring, with a trend of improving survival. EMERALD‑3 shows we can now significantly reduce the risk of disease progression with STRIDE as the immunotherapy backbone alongside lenvatinib and TACE."
AstraZeneca is in discussions with global regulatory authorities regarding these positive data, and the company anticipates that the trial’s outcomes could support a new indication for the STRIDE regimen in the embolization‑eligible, unresectable HCC setting. The results strengthen AstraZeneca’s oncology pipeline, potentially expanding its market share in a disease area with high unmet need and limited effective therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.